Ann: Director Resignation, page-157

Ahh yes, I took another look at the website. It sounds like a wind up might happen, though we may also see the business continuing to trade and ASM selling to an another institution down the track. If the conflicts are resolved and the business has a few months of stability, it may be investible enough for ASM to exit via ASX. Would love to know what their plans and expectations are.

Obviously I would like to see DNA trade after a settlement and the new CEO being given at least a year or two, if DNA becomes investible again (but still high risk given location etc) then a more conventional valuation of several times higher than 8c is concievable. It won't make 50m (pre management fee) like FY17, but 25m is probably a very achievable base. That's up to 3.7c per share to div out if shares cancelled and debt retired. Can't see it below 30c eventually in that situation.